187 related articles for article (PubMed ID: 37615532)
1. Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report.
He X; Hou L; Bai J; Sun C; Wang D; An G
Anticancer Drugs; 2024 Jan; 35(1):101-108. PubMed ID: 37615532
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
Iwama E; Zenke Y; Sugawara S; Daga H; Morise M; Yanagitani N; Sakamoto T; Murakami H; Kishimoto J; Matsumoto S; Nakanishi Y; Goto K; Okamoto I
Eur J Cancer; 2022 Feb; 162():99-106. PubMed ID: 34959152
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab Deruxtecan in
Li BT; Smit EF; Goto Y; Nakagawa K; Udagawa H; Mazières J; Nagasaka M; Bazhenova L; Saltos AN; Felip E; Pacheco JM; Pérol M; Paz-Ares L; Saxena K; Shiga R; Cheng Y; Acharyya S; Vitazka P; Shahidi J; Planchard D; Jänne PA;
N Engl J Med; 2022 Jan; 386(3):241-251. PubMed ID: 34534430
[TBL] [Abstract][Full Text] [Related]
4. Metastatic
Yun KM; Bazhenova L
BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37156567
[TBL] [Abstract][Full Text] [Related]
5. FDA Gives Nod to T-DXd for HER2-Mutant NSCLC.
Cancer Discov; 2022 Oct; 12(10):2224. PubMed ID: 35984233
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Genomic Features of
Tan AC; Saw SPL; Chen J; Lai GGY; Oo HN; Takano A; Lau DPX; Yeong JPS; Tan GS; Lim KH; Skanderup AJ; Chan JWK; Teh YL; Rajasekaran T; Jain A; Tan WL; Ng QS; Kanesvaran R; Lim WT; Ang MK; Tan DSW
JCO Precis Oncol; 2022 Oct; 6():e2200278. PubMed ID: 36240473
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond.
Perez J; Garrigós L; Gion M; Jänne PA; Shitara K; Siena S; Cortés J
Expert Opin Biol Ther; 2021 Jul; 21(7):811-824. PubMed ID: 33759669
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Indini A; Rijavec E; Grossi F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
[TBL] [Abstract][Full Text] [Related]
10. Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring
Kato Y; Kato Y; Minegishi Y; Suzuki T; Nakamichi S; Matsumoto M; Miyanaga A; Noro R; Kubota K; Terasaki Y; Seike M; Gemma A
Onco Targets Ther; 2021; 14():5315-5319. PubMed ID: 34848974
[TBL] [Abstract][Full Text] [Related]
11. Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.
Sato M; Han Q; Mori R; Mizuta K; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM
Anticancer Res; 2024 Apr; 44(4):1499-1504. PubMed ID: 38538002
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab Deruxtecan in Patients With
Goto K; Goto Y; Kubo T; Ninomiya K; Kim SW; Planchard D; Ahn MJ; Smit EF; de Langen AJ; Pérol M; Pons-Tostivint E; Novello S; Hayashi H; Shimizu J; Kim DW; Kuo CH; Yang JC; Pereira K; Cheng FC; Taguchi A; Cheng Y; Feng W; Tsuchihashi Z; Jänne PA
J Clin Oncol; 2023 Nov; 41(31):4852-4863. PubMed ID: 37694347
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of Non-Small Cell Lung Cancer with HER2 Alterations].
Takakura T; Yamamoto N
Gan To Kagaku Ryoho; 2023 Jul; 50(7):768-772. PubMed ID: 37496218
[TBL] [Abstract][Full Text] [Related]
14. Targeting HER2 May Overtake Chemo, Immunotherapy in NSCLC.
Cancer Discov; 2021 Dec; 11(12):OF3. PubMed ID: 34675060
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective.
Aoki M; Iwasa S; Boku N
Gastric Cancer; 2021 May; 24(3):567-576. PubMed ID: 33646464
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer.
O'Rourke K
Cancer; 2022 Mar; 128(5):938. PubMed ID: 35147987
[No Abstract] [Full Text] [Related]
17. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Tsurutani J; Iwata H; Krop I; Jänne PA; Doi T; Takahashi S; Park H; Redfern C; Tamura K; Wise-Draper TM; Saito K; Sugihara M; Singh J; Jikoh T; Gallant G; Li BT
Cancer Discov; 2020 May; 10(5):688-701. PubMed ID: 32213540
[TBL] [Abstract][Full Text] [Related]
18. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
[TBL] [Abstract][Full Text] [Related]
19. The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug.
Jørgensen JT
Oncology; 2023; 101(12):836-842. PubMed ID: 37651992
[TBL] [Abstract][Full Text] [Related]
20. Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.
Nützinger J; Bum Lee J; Li Low J; Ling Chia P; Talisa Wijaya S; Chul Cho B; Min Lim S; Soo RA
Lung Cancer; 2023 Dec; 186():107385. PubMed ID: 37813015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]